Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy

TY - JOUR

T1 - Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy

AU - Witting, Nanna

AU - Kruuse, Christina

AU - Nyhuus, Bo

AU - Prahm, Kira P

AU - Citirak, Gulsenay

AU - Lundgaard, Stine J

AU - von Huth, Sebastian

AU - Vejlstrup, Niels

AU - Lindberg, Ulrich

AU - Krag, Thomas O

AU - Vissing, John

N1 - © 2014 American Neurological Association.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - OBJECTIVE: Patients with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy lack neuronal nitric oxide synthase (nNOS). nNOS mediates physiological sympatholysis, thus ensuring adequate blood supply to working muscle. In mice lacking dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardiac muscle performance. Sildenafil also improves blood flow in patients with BMD. We therefore hypothesized that sildenafil would improve blood flow, maximal work capacity, and heart function in patients with BMD.METHODS: A randomized, double-blind, placebo-controlled crossover design with two 4-week periods of treatment, separated by 2-week washout was used. We assessed brachial artery blood flow during maximal handgrip exercise, 6-minute walk test, maximal oxidative capacity, and life quality; cardiac function was evaluated by magnetic resonance imaging (MRI) at rest and during maximal handgrip exercise. Muscle nNOS and PDE5 were tested with Western blotting in 5 patients.RESULTS: Sixteen patients completed all skeletal muscle evaluations, and 13 completed the cardiac MRI investigations. Sildenafil had no effect on any of the outcome parameters. No serious adverse effects were recorded. PDE5 and nNOS were deficient in 5 of 5 biopsies.INTERPRETATION: Despite positive evidence from animal models of dystrophinopathy and physiological findings in patients with BMD, this double-blind, placebo-controlled clinical study showed no effect of sildenafil on blood flow, maximal work capacity, and heart function in adults with BMD. This discrepancy may be explained by a significant downregulation of PDE5 in muscle.

AB - OBJECTIVE: Patients with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy lack neuronal nitric oxide synthase (nNOS). nNOS mediates physiological sympatholysis, thus ensuring adequate blood supply to working muscle. In mice lacking dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardiac muscle performance. Sildenafil also improves blood flow in patients with BMD. We therefore hypothesized that sildenafil would improve blood flow, maximal work capacity, and heart function in patients with BMD.METHODS: A randomized, double-blind, placebo-controlled crossover design with two 4-week periods of treatment, separated by 2-week washout was used. We assessed brachial artery blood flow during maximal handgrip exercise, 6-minute walk test, maximal oxidative capacity, and life quality; cardiac function was evaluated by magnetic resonance imaging (MRI) at rest and during maximal handgrip exercise. Muscle nNOS and PDE5 were tested with Western blotting in 5 patients.RESULTS: Sixteen patients completed all skeletal muscle evaluations, and 13 completed the cardiac MRI investigations. Sildenafil had no effect on any of the outcome parameters. No serious adverse effects were recorded. PDE5 and nNOS were deficient in 5 of 5 biopsies.INTERPRETATION: Despite positive evidence from animal models of dystrophinopathy and physiological findings in patients with BMD, this double-blind, placebo-controlled clinical study showed no effect of sildenafil on blood flow, maximal work capacity, and heart function in adults with BMD. This discrepancy may be explained by a significant downregulation of PDE5 in muscle.

KW - Adult

KW - Analysis of Variance

KW - Cyclic Nucleotide Phosphodiesterases, Type 5

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Hand Strength

KW - Humans

KW - Locomotion

KW - Magnetic Resonance Imaging

KW - Male

KW - Muscle, Skeletal

KW - Muscular Dystrophy, Duchenne

KW - Myocardium

KW - Nitric Oxide Synthase Type I

KW - Piperazines

KW - Purines

KW - Regional Blood Flow

KW - Sulfones

KW - Vasodilator Agents

KW - Young Adult

U2 - 10.1002/ana.24216

DO - 10.1002/ana.24216

M3 - Journal article

C2 - 25042931

SN - 0364-5134

VL - 76

SP - 550

EP - 557

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -